Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.

doi:10.1016/j.ejca.2024.114127

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.

European journal of cancer (Oxford, England : 1990) - 1 Jul 2024

Roma Cristin, Esposito Abate Riziero, Sacco Alessandra, Califano Daniela, Arenare Laura, Bergantino Francesca, Pisano Carmela, Cecere Sabrina Chiara, Scambia Giovanni, Lorusso Domenica, Artioli Grazia, Tasca Giulia, Spina Anna, Russo Daniela, Gadducci Angiolo, De Angelis Carmine, Bologna Alessandra, Marchini Sergio, Capoluongo Ettore Domenico, Perrone Francesco, Pignata Sandro, Normanno Nicola

Abstract excerpt

BACKGROUND: Homologous Recombination Deficiency (HRD) status predicts response to treatment with poly(ADP-ribose) polymerase inhibitors in Ovarian Cancer (OC) patients. The Myriad myChoiceCDx Assay is approved by Food and Drug Agency for the HRD assessment. Here we compared the HRD status obtained by three commercial panels with the results from Myriad reference test. METHODS: The HRD analysis was performed on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Genetic Testing

Share to Genomic Instability

Share to Homologous Recombination

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 38797038
DOI: 10.1016/j.ejca.2024.114127

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.PMID 38797038Read ↗

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trialSemantic proximity Read ↗

Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World CohortSemantic proximity Read ↗

High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.Semantic proximity Read ↗

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assaySemantic proximity Read ↗

Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.Semantic proximity Read ↗

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer DiagnosisSemantic proximity Read ↗

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian CarcinomaSemantic proximity Read ↗

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinomaSemantic proximity Read ↗

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialSemantic proximity Read ↗

Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.Semantic proximity Read ↗

Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.Semantic proximity Read ↗

HRD-One: CLINICAL VALIDATION AND PERFORMANCE ASSESSMENT. Comparison between Myriad’s myChoice®, SOPHiA GENETICS® SOPHiA Homologous Recombination Solution and AmoyDx® HRD Focus PanelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.